Allergic contact dermatitis: a case series and review for the ophthalmologist 
INTRODUCTION
Causes of an itchy, red eyelid include eczema and psoriasis, seborrhoeic dermatitis, meibomitis/ blepharitis and rosacea, dermatomyositis, infections, infestations and malignancy.
Allergic contact dermatitis (ACD) is the commonest cause of eyelid dermatitis. 1e4 5 While many patients never get to the stage of being referred to an ophthalmologist, up to 13% of all patients with ACD have been reported to present with eyelid involvement. 1e3 This may be the only affected site and may result in delayed diagnosis. 4 6 Eyelid inflammation tends to be attributed by ophthalmologists more typically, and potentially incorrectly, to local causes, such as topical medications and eye-drops.
Eczema may result from exogenous/endogenous factors. Contact dermatitis is due to exogenous factors and can be irritant or allergic. Irritant contact dermatitis, such as toxic reactions to eyedrops, is caused by direct damage and penetration of the skin, and represents only approximately 15% of patients with persistent eyelid features. 2 3 On the other hand, ACD is a delayed type IV hypersensitivity reaction to a specific allergen and accounts for the majority. 2 3 5 7 8 Atopic eczema, which is endogenous, represents only 11e39%. 2 3 9 While this is well described in the dermatological literature, we believe that ophthalmologists are less aware of the periorbital manifestations and management of this condition. This descriptive study of 14 patients referred to our oculoplastic units for a second/third opinion highlights this delay to diagnosis incurred prior to referral. In addition, we review the current literature and detail the important features of ACD.
MATERIALS AND METHODS
A retrospective non-comparative case series was performed of patients referred between September 2006 and September 2008 to two specialist oculoplastic centres. Fourteen consecutive patients with patch test proven allergens from two independent units were included. The causes, clinical features, management and outcome are described in relation to these patients.
An up-to-date appraised review of the literature was performed, including research from the Ovid Medline and Embase databases. International papers were incorporated. Review articles, large case series and randomised controlled trials were included after appraisal by two separate authors. The main outcome measure was evidence-based literature with clinical relevance.
RESULTS
We studied 14 patients (10 female, age range 5e72 years). Eleven patients were referred by an ophthalmologist for a second opinion and the remainder by their general practitioners. Clinical details of each patient are included in table 1. All patients presented with bilateral upper and lower eyelid involvement, with one exception (Case 10) that had unilateral disease secondary to an eyebrow ring. Most complained of sore, itchy eyelids with swelling of the skin. Some showed lichenification, and in two patients (Cases 2 and 6) post-inflammatory hyperpigmentation was the most striking feature (see figures 1AeF, 2A,B) .
The duration of symptoms varied from 2 weeks to 4.5 years (median 1 year, mean 13 months). Eight patients had had symptoms for 6 months or more, of whom five gave a history longer than a year. Many had tried topical emollients and steroids, but it was only upon withdrawal of the allergen that their disease improved. All of our patients were referred to a dermatologist for patch testing.
Two important features of our patients are the range and type of allergens involved. 
DISCUSSION
Eyelid dermatitis is not uncommon, with one author 9 reporting involvement in as many as 10% of all general dermatology outpatients. The differential diagnosis includes contact and atopic eczema, seborrhoeic dermatitis, blepharitis, rosacea, psoriasis, dermatomyositis, impetigo and cutaneous T cell lymphoma.
Acute ACD may present with erythema and macules, papules and/or vesicles. However, blisters are rare on the eyelids. Lichenification, scaling and fissuring are features of more chronic disease. The incidence of ACD as a cause of eyelid dermatitis varies from 29 to 77% of patients reported, 1e3 5 7 8 10 and has been found to be the most likely cause if all four eyelids are involved. 10 It is more common in middle-aged patients with less pigmented skin. Amin et al 11 reported 85.4% of their patients with ACD as Caucasian in origin with the greatest prevalence in the 41e70-year-old age range. Females are most frequently affected (61.8e90% of patients) because of the use of cosmetics. 
Immune process
Two stages are necessary in the development of ACDdan initial immune-mediated sensitisation to the allergen and then Complete resolution elicitation of the inflammatory response. Sensitisation involves penetration of an allergen through the skin and binding to Langerhans antigen-presenting cells. These cells migrate to the lymph nodes and sensitise naïve T lymphocytes, which then relocate themselves back in the skin but throughout the skin. The inflammatory response is elicited by re-exposure to the allergen. Most environmental allergens are haptensdsimple <500 Da electrophilic molecules that must link to proteins to form a complete antigen before they can sensitise. 12 There are more than 2800 known environmental allergens, 13 but not all are haptens. If the hapten complexes with a non-immunogenic carrier, then tolerance is induced, rather than sensitisation.
14 The carriers for contact allergens are HLA-DR or class II antigens on the surface of the Langerhan cells. 15 Because ACD is immune-mediated, compromised immunity is associated with decreased reactivity or anergy. The ageing process modulates ACD, possibly due to a decrease in density of antigen presenting cells and production of proinflammatory cytokines. 16 In addition, children and infants can be affected by ACD. It is unclear when immunocompentence is achieved, but patch testing has been performed in infants younger than 2 years of age. 17 More typically, ACD is seen in older children.
Investigation
Skin biopsies are unlikely to distinguish between ACD and other forms of eczema but may help to exclude impetigo and lymphoma. Irritant and ACD both show spongiosis and a lymphocyte infiltrate. Acute irritant contact eczema usually shows more ballooning degeneration and necrotic keratocytes, whereas ACD shows more spongiosis of the epidermis. 18 Patch testing is the key investigation used to identify allergens. Frequent contact allergens in eyelid ACD are shown in table 2. Eyelids are particularly susceptible to ACD because the skin is thinner (thickness of 0.55 mm) than on the rest of the face (2.0 mm thick). This allows easier penetration of the allergen than at other sites, and eyelid dermatitis may therefore be the only manifestation. 11 In addition, eyelids may manifest a reaction without direct contact of the allergen at this site.
A thorough history should be taken to identify possible allergens. Details of cosmetics, hobbies and occupation may be relevant. The eyes, eyelids, face and hands (including nails) should be carefully examined.
Patch testing involves application of allergens under Finn Chambers to the patient's back. Reactions are read at varying intervals. Standard batteries of patch tests, for example European standard series, TRUE test and North American CD Group series, 19 do not include every relevant eyelid allergen, and the test should be adjusted for each patient. Guin found that 66 out of a total of 167 patients with ACD would have remained undiagnosed if the TRUE test was used alone. 9 Similarly, Katz and Sherertz 4 found that the TRUE test alone would have detected only 37% of ACD allergens, and the North American CD Group only 42% of allergens. The most common relevant allergens are the patient's own personal care products.
While patch testing often provides the answer for the patient, interpretation should be performed by an experienced clinician. Untrained interpretation exposes the patient to incorrect overand undertesting, deceptive results and potentially unwanted sensitisation. Interpretation involves being able to separate irritant and allergic reactions, determining the relevance of the antigen, and the optimum reading time and appreciation of cross-reactions and coreactivity.
False positives can occur if the allergen causes an irritant rather than allergic response. The test may need to be repeated with the allergen at a lower concentration. In addition, even if a chemical is found to be allergenic, it cannot be assumed that it is causative. The relevance of the antigen is important. A provocation test or repeat open application testing may be necessary. This involves the patient applying the commercial product to their skin several times daily for 1e2 weeks. 20 Most false-negative responses can be avoided by performing a second reading of the test sites 48 h after the first. Some studies advocate readings at 4e7 days, especially in older patients, to ensure any allergic response is elicited. 21 22 Neomycin reactions may take longer: one study showed that half are not evident until 96 h. 23 In addition, if too low a concentration is used in testing, sensitisation may not occur. Sensitisation is dependent on the dose of chemical per unit area of skin (up to a limit of 0.1 cm 2 ). 24 Concentrations of ophthalmic preparations may need to be tested at a higher level owing to difficulty in penetrating the skin on the back. 25 Side effects of patch testing include a severe local reaction or flare reaction at a distant site, an 'angry back/excited skin' syndrome where numerous positive reaction occur, pigment changes, scarring and keloids, infections and potentially anaphylaxis. 26 For all of these reasons, patch testing should be performed by an experienced dermatologist.
Treatment
It is well established that patients may occasionally continue to have symptoms even after avoidance of the allergen. 27 28 Treatment for symptom relief is therefore required in addition to simply identifying responsible allergens.
Treatment should include emollients, treatment of secondary infection if present and downregulation of the immune response. Topical antipruritics should be avoided because of the risk of secondary sensitisation. 29 Glucocorticosteroids are usually the primary choice for immune modulation, and their effective treatment of ACD is well documented. 30e32 Inflammation is reduced by suppressing the recruitment of polymorphonuclear leucocytes and reversing capillary permeability. Topical steroids are usually sufficient, and treatment should be limited to 2e3 weeks' duration. Lowpotency steroids such as hydrocortisone and desonide are safer for use on the face, though stronger steroids such as clobetasone proprionate or betamethasone diproprionate are used for moderate to severe disease. 33 Longstanding application of topical steroids is associated with skin atrophy, telangiectases and acneiform reactions. If more than 20% of the body surface area is involved, or if there are bullae or extensive facial involvement, then treatment should be considered with systemic steroids.
It is important to be aware that topical steroids may themselves be allergenic, as seen in case 12. One study 34 of 31 patients with ACD who had worsened or had shown no response to topical corticosteroid treatment found that 22% had a positive patch test result to the steroid itself. In other studies, 35 36 the steroid has been implicated in 0.2e5%.
Ascomyscins such as tacrolimus (TK506) (Protopic oinment 0.03% or 0.1%) and pimecrolimus (ASM 981) (Elidel cream) have recently been introduced as treatment options and provide a solution for thin-skin areas, for example the face and eyelids. 37 38 They are topical calcineurin inhibitors and cause a reduction in interleukin, leucotriene, histamine and serotonin release, thereby effectively suppressing the immune response. 29 39 Both agents target the human epidermal Langerhans cell 40 and have been shown to inhibit the elicitation phase of ACD in a mouse model. 41 In addition, a study in humans found that tacrolimus also suppresses the sensitisation phase. 42 Tacrolimus ointment at concentrations of both 0.03% and 0.1% has been found to be an effective treatment for nickel-induced steroid resistant ACD in adult and paediatric patients. Safety and efficacy of usage has also been reported in children aged 2 years or older. 12 A 0.1% concentration is probably more effective 43e45 but is more frequently a cause of itching and burning. These rapidly decrease after the first week of treatment. Although Ciclosporin A is also a successful calcineurin inhibitor, it has limited penetration through the epidermis and limited topical application for this condition. 30 46 47 Ascomycins have been compared with topical steroids. A small double-blind RCT pilot study 48 examining nickel ACD looked at four treatment groupsdpimecrolimus 1% cream, tacrolimus 0.1% ointment, clobetasol 0.05% ointment, triamcinolone 0.1% ointmentdand two control groups of topical vehicle application. No statistically significant differences were found between any of the groups, although the treatment groups showed a clear trend towards being more effective than control. However, Saripalli et al 49 induced nickel ACD in patients and found that tacrolimus was significantly more effective than vehicle. Alomar et al 50 corroborated this finding. Similarly, pimecrolimus at 0.2% and 0.6% formulations has successfully treated nickel-induced ACD. 51 Other treatment options for more widespread disease away from the eyes, patients who are unresponsive to the above treatments or those who cannot avoid the provoking factors include phototherapydultraviolet A photochemotherapy (oral psoralen photochemotherapy) and shortwave UVB light. In addition, use of Grenz rays 52 and systemic immunosuppressants 53 such as azathioprine and mycophenolate mofatil have been described in ACD.
In our study, all of the patients improved with removal of the allergen with/without a short course of topical immunosuppressants.
In conclusion, eyelid dermatitis may be the only dermatological manifestation of ACD (see summary in table 3). A delay in diagnosis commonly hinders appropriate treatment and avoidance of allergens. In our experience, marked delays were due to a lack of awareness of the condition by referring ophthalmologists. Improved awareness is essential. In addition, it should be remembered that the corticosteroids used to treat ACD may in fact be causative themselves, and patients who are unresponsive to treatment ought to have corticosteroids included as potential allergens in their patch testing.
